AMT-116 in Patients with Solid Tumors
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Multitude Therapeutics Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT06782334
- Locations
- ๐จ๐ณ
Fujian Cancer Hospital, Fuzhou, Fujian, China
๐จ๐ณDongguan People's Hospital, Dongguan, Guangdong, China
๐จ๐ณZhujiang Hospital of Southern Medical University(The Second Clinical Medical College), Guangzhou, Guangdong, China
AMT-676 in Patients With Advanced Solid Tumors
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Multitude Therapeutics Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06400485
- Locations
- ๐ฆ๐ธ
Carolina Biooncology Institute, Huntersville, American Samoa
๐ฆ๐ธJohn Hopkins Sidney Kimmel Comprehensive Cancer Center, Philadelphia, American Samoa
๐ฆ๐ธSouth Texas Accelerated Research Therapeutics (start) San Antonio, San Antonio, American Samoa
AMT-253 in Patients With Advanced Solid Tumours
- Conditions
- Malignant MelanomaAdvanced Solid Tumors
- Interventions
- Drug: AMT-253 for injection
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Multitude Therapeutics Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT06209580
- Locations
- ๐จ๐ณ
Beijing Cancer Hospital, Beijing, Beijing, China
AMT-116 in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Multitude Therapeutics Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05725291
- Locations
- ๐บ๐ธ
Sarah Cannon Research Institute, Denver, Colorado, United States
๐บ๐ธMary Crowley Cancer Research Centers, Dallas, Texas, United States
๐ฆ๐ธCarolina BioOncology Institute, LLC, Cary, American Samoa
AMT-151 in Patients With Selected Advanced Solid Tumours
- Conditions
- Advanced Solid TumorPancreatic Ductal AdenocarcinomaEndometrial AdenocarcinomaEndometrial Serous AdenocarcinomaLung AdenocarcinomaAdvanced CancerAdvanced CarcinomaOvarian CancerOvarian CarcinomaEndometrial Clear Cell Adenocarcinoma
- Interventions
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Multitude Therapeutics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05498597
- Locations
- ๐ฆ๐บ
Chris O'Brien Lifehouse, Sydney, New South Wales, Australia
๐ฆ๐บCancer Research SA, Adelaide, South Australia, Australia
๐ฆ๐บOne Clinical Research (OCR), Perth, Western Australia, Australia